This is an exciting time to build on Sunovion’s track record of providing important new treatment options, while focusing each day on serving and creating value for patients.
Antony Loebel, M.D.
President and Chief Executive Officer
Dr. Antony Loebel is President and CEO of Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.
Sunovion’s track record of discovery, development and commercialization of important psychiatric, neurological and respiratory therapies has included Latuda® (lurasidone HCl), Brovana® (arformoterol tartrate), Aptiom® (eslicarbazepine acetate) and Lonhala® Magnair® (glycopyrrolate) Inhalation Solution and, most recently, KYNMOBI™ (apomorphine HCl) sublingual film.
Dr. Loebel joined the Company in 2007. His prior industry experience includes seven years in drug development and medical affairs roles at Pfizer. He serves as an Executive Leadership Team member of Sunovion and an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sunovion. Dr. Loebel also serves on the Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors and previously served on the Massachusetts Biotechnology Council (MassBio) Board of Directors.
During his tenure at Sunovion, Dr. Loebel has provided strategic direction and leadership of Research & Development (R&D), including overseeing the Global Clinical Development organization. In this role, he directed initiatives designed to improve global R&D operational efficiency and to address unmet medical needs through innovation in drug development. Dr. Loebel’s scientific work has led to the publication of numerous articles on the diagnosis and treatment of severe mental illness.
Dr. Loebel is a board-certified psychiatrist, a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a member of the American College of Neuropsychopharmacology (ACNP). For his achievements in advancing new treatments for central nervous system (CNS) disorders, Dr. Loebel received the 2015 Award for Leadership from the International Society for CNS Drug Development (ISCDD) and the 2019 CNS Summit Leadership Award. Selected by PharmaVOICE in 2019 and 2013 as one of the “100 Most Inspiring People” in the pharmaceutical industry, Dr. Loebel is widely recognized by his peers as an innovative and collaborative leader guided by his dedication to patients.
Dr. Loebel earned a M.D. from the University of Washington School of Medicine in Seattle. He completed his residency in Psychiatry and a research fellowship in Clinical Neurosciences at Zucker Hillside Hospital (Northwell Health) in Glen Oaks, New York. Dr. Loebel holds a Bachelor of Arts degree with Majors in Zoology and English (with Distinction) from the University of Washington.